Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin's Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. "We are excited to partner with Cellectar Biosciences to evaluate iopofosine in patients with mycosis fungoides," said Dr. Steven T. Rosen, executive vice president and director emeritus, Comprehensive Cancer Center and Beckman Research Institute of City of Hope. "Its unique delivery platform targeting all tumor ...